U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C17H26ClN
Molecular Weight 279.8486
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SIBUTRAMINE

SMILES

CC(C)CC(C1(CCC1)c2ccc(cc2)Cl)N(C)C

InChI

InChIKey=UNAANXDKBXWMLN-UHFFFAOYSA-N
InChI=1S/C17H26ClN/c1-13(2)12-16(19(3)4)17(10-5-11-17)14-6-8-15(18)9-7-14/h6-9,13,16H,5,10-12H2,1-4H3

HIDE SMILES / InChI

Molecular Formula C17H26ClN
Molecular Weight 279.8486
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment:: description was created based on several sources, including http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm228830.htm

Subitramine is a potent inhibitor of monoamines (serotonin, dopamine, noradrenaline) reuptake that was approved by FDA for the treatmen of obesity. Sibutramine is metabolized to metabolites M1 and M2 which are more active toward the monoamine transporters.The drug was withdrawn from the market because of clinical trial data indicating an increased risk of heart attack and stroke. It was sold under a variety of brand names including Reductil, Meridia and Sibutrex.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P31645
Gene ID: 6532.0
Gene Symbol: SLC6A4
Target Organism: Homo sapiens (Human)
298.0 nM [Ki]
Target ID: Q01959
Gene ID: 6531.0
Gene Symbol: SLC6A3
Target Organism: Homo sapiens (Human)
943.0 nM [Ki]
Target ID: P23975
Gene ID: 6530.0
Gene Symbol: SLC6A2
Target Organism: Homo sapiens (Human)
5451.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
MERIDIA

Approved Use

MERIDIA is indicated for the management of obesity, including weight loss and maintenance of weight loss, and should be used in conjunction with a reduced calorie diet.

Launch Date

8.801568E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
4 ng/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DESMETHYLSIBUTRAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
7.12 ng/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DESMETHYLSIBUTRAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
4067.7 pg/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DESMETHYLSIBUTRAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
6.4 ng/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIDESMETHYLSIBUTRAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
8.09 ng/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIDESMETHYLSIBUTRAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
6579.8 pg/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIDESMETHYLSIBUTRAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
4368.5 pg/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SIBUTRAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
25.5 ng × h/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DESMETHYLSIBUTRAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
133.03 ng × h/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DESMETHYLSIBUTRAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
100736.1 pg × h/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DESMETHYLSIBUTRAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
92.1 ng × h/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIDESMETHYLSIBUTRAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
205.86 ng × h/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIDESMETHYLSIBUTRAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
194500.9 pg × h/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIDESMETHYLSIBUTRAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
23296.9 pg × h/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SIBUTRAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
22.31 h
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DESMETHYLSIBUTRAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
25.5 h
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DESMETHYLSIBUTRAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
17.2 h
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIDESMETHYLSIBUTRAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
23.07 h
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIDESMETHYLSIBUTRAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
23.6 h
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIDESMETHYLSIBUTRAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
3.6 h
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SIBUTRAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
6%
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DESMETHYLSIBUTRAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
6%
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIDESMETHYLSIBUTRAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
20 mg 1 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: 14
unhealthy, adult
n = 2068
Health Status: unhealthy
Condition: obesity
Age Group: adult
Sex: unknown
Population Size: 2068
Sources: Page: 14
Disc. AE: Hypertension, Tachycardia...
AEs leading to
discontinuation/dose reduction:
Hypertension (0.4%)
Tachycardia (0.4%)
Sources: Page: 14
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
unhealthy, mean 32 years
n = 7
Health Status: unhealthy
Condition: vasovagal syncope
Age Group: mean 32 years
Sex: M+F
Population Size: 7
Sources:
Disc. AE: Palpitations...
Other AEs: Palpitations...
AEs leading to
discontinuation/dose reduction:
Palpitations (1 patient)
Other AEs:
Palpitations (2 patients)
Sources:
20 mg 1 times / day multiple, oral
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, mean 32 years
n = 7
Health Status: unhealthy
Condition: vasovagal syncope
Age Group: mean 32 years
Sex: M+F
Population Size: 7
Sources:
Other AEs: Palpitations, Paresthesia...
Other AEs:
Palpitations (1 patient)
Paresthesia (1 patient)
Anxiety (1 patient)
Insomnia (1 patient)
Fatigue (1 patient)
Sources:
20 mg 1 times / day multiple, oral
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, mean 42.9 years
n = 146
Health Status: unhealthy
Condition: obesity
Age Group: mean 42.9 years
Sex: M+F
Population Size: 146
Sources:
Disc. AE: Hypertension, Tachycardia...
Other AEs: Dry mouth, Anorexia...
AEs leading to
discontinuation/dose reduction:
Hypertension (<1.4%)
Tachycardia (<3%)
Other AEs:
Dry mouth (32.2%)
Anorexia (32.2%)
Insomnia (10.3%)
Increased appetite (11.6%)
Nausea (8.2%)
Dyspepsia (5.5%)
Nervousness (12.3%)
Asthenia (8.9%)
Dizziness (12.3%)
Constipation (12.3%)
Rash (4.1%)
Palpitation (4.1%)
Vasodilation (4.8%)
Dyspnea (1.4%)
Taste perversion (4.1%)
Hypertension (1.4%)
Sweating (4.1%)
Tachycardia (6.8%)
Ecchymosis (1.4%)
Paresthesia (3.4%)
Sources:
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, mean 43.3 years
n = 203
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.3 years
Sex: M+F
Population Size: 203
Sources:
Disc. AE: Hypertension, Tachycardia...
Other AEs: Dry mouth, Anorexia...
AEs leading to
discontinuation/dose reduction:
Hypertension (<2%)
Tachycardia (<3%)
Other AEs:
Dry mouth (16.7%)
Anorexia (18.7%)
Insomnia (9.4%)
Increased appetite (16.7%)
Nausea (3.4%)
Dyspepsia (4.4%)
Nervousness (6.4%)
Asthenia (7.9%)
Dizziness (7.9%)
Constipation (10.8%)
Rash (4.9%)
Palpitation (4.9%)
Vasodilation (2%)
Dyspnea (1.5%)
Taste perversion (2%)
Hypertension (4.9%)
Sweating (1%)
Tachycardia (4.4%)
Ecchymosis (0.5%)
Paresthesia (3.9%)
Sources:
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 151
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 151
Sources:
Disc. AE: Hypertension, Tachycardia...
Other AEs: Dry mouth, Anorexia...
AEs leading to
discontinuation/dose reduction:
Hypertension (2%)
Tachycardia (3%)
Other AEs:
Dry mouth (31.8%)
Anorexia (31.8%)
Insomnia (24.5%)
Increased appetite (21.2%)
Nausea (12.6%)
Dyspepsia (12.6%)
Nervousness (11.3%)
Asthenia (10.6%)
Dizziness (7.9%)
Constipation (7.9%)
Rash (7.3%)
Palpitation (6%)
Vasodilation (5.3%)
Dyspnea (4.6%)
Taste perversion (4.6%)
Hypertension (3.3%)
Sweating (2.6%)
Tachycardia (2.6%)
Ecchymosis (2%)
Paresthesia (1.3%)
Sources:
5 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 169
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 169
Sources:
Disc. AE: Hypertension, Tachycardia...
Other AEs: Dry mouth, Anorexia...
AEs leading to
discontinuation/dose reduction:
Hypertension (<1.2%)
Tachycardia (<1.8%)
Other AEs:
Dry mouth (11.8%)
Anorexia (18.9%)
Insomnia (8.3%)
Increased appetite (16.6%)
Nausea (4.1%)
Dyspepsia (4.1%)
Nervousness (5.3%)
Asthenia (7.1%)
Dizziness (8.9%)
Constipation (13%)
Rash (4.1%)
Vasodilation (2.4%)
Dyspnea (0.6%)
Taste perversion (1.2%)
Hypertension (1.2%)
Sweating (1.2%)
Tachycardia (1.8%)
Ecchymosis (1.2%)
Paresthesia (2.4%)
Sources:
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
unhealthy, mean 44.2 years
n = 196
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.2 years
Sex: M+F
Population Size: 196
Sources:
Disc. AE: Hypertension, Tachycardia...
Other AEs: Dizziness, Dry mouth...
AEs leading to
discontinuation/dose reduction:
Hypertension (<2%)
Tachycardia (<3%)
Other AEs:
Dizziness (8.2%)
Dry mouth (25.5%)
Anorexia (21.4%)
Insomnia (10.2%)
Increased appetite (14.3%)
Nausea (5.1%)
Dyspepsia (8.2%)
Nervousness (7.7%)
Asthenia (6.1%)
Constipation (11.7%)
Rash (7.1%)
Palpitation (2.6%)
Vasodilation (2%)
Dyspnea (1%)
Taste perversion (2.6%)
Hypertension (5.1%)
Sweating (2.6%)
Tachycardia (7.7%)
Ecchymosis (3.1%)
Paresthesia (2%)
Sources:
1 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy, mean 44.5 years
n = 149
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.5 years
Sex: M+F
Population Size: 149
Sources:
Disc. AE: Hypertension, Tachycardia...
Other AEs: Dry mouth, Anorexia...
AEs leading to
discontinuation/dose reduction:
Hypertension (<2%)
Tachycardia (<0.7%)
Other AEs:
Dry mouth (6%)
Anorexia (20.1%)
Insomnia (12.1%)
Increased appetite (11.4%)
Nausea (3.4%)
Dyspepsia (4%)
Nervousness (4.7%)
Asthenia (2.7%)
Dizziness (4.7%)
Constipation (6.7%)
Rash (5.4%)
Palpitations (2%)
Vasodilation (1.3%)
Dyspnea (1.3%)
Taste perversion (0.7%)
Hypertension (2%)
Tachycardia (0.7%)
Paresthesia (2%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Hypertension 0.4%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: 14
unhealthy, adult
n = 2068
Health Status: unhealthy
Condition: obesity
Age Group: adult
Sex: unknown
Population Size: 2068
Sources: Page: 14
Tachycardia 0.4%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: 14
unhealthy, adult
n = 2068
Health Status: unhealthy
Condition: obesity
Age Group: adult
Sex: unknown
Population Size: 2068
Sources: Page: 14
Palpitations 1 patient
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
unhealthy, mean 32 years
n = 7
Health Status: unhealthy
Condition: vasovagal syncope
Age Group: mean 32 years
Sex: M+F
Population Size: 7
Sources:
Palpitations 2 patients
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
unhealthy, mean 32 years
n = 7
Health Status: unhealthy
Condition: vasovagal syncope
Age Group: mean 32 years
Sex: M+F
Population Size: 7
Sources:
Anxiety 1 patient
20 mg 1 times / day multiple, oral
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, mean 32 years
n = 7
Health Status: unhealthy
Condition: vasovagal syncope
Age Group: mean 32 years
Sex: M+F
Population Size: 7
Sources:
Fatigue 1 patient
20 mg 1 times / day multiple, oral
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, mean 32 years
n = 7
Health Status: unhealthy
Condition: vasovagal syncope
Age Group: mean 32 years
Sex: M+F
Population Size: 7
Sources:
Insomnia 1 patient
20 mg 1 times / day multiple, oral
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, mean 32 years
n = 7
Health Status: unhealthy
Condition: vasovagal syncope
Age Group: mean 32 years
Sex: M+F
Population Size: 7
Sources:
Palpitations 1 patient
20 mg 1 times / day multiple, oral
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, mean 32 years
n = 7
Health Status: unhealthy
Condition: vasovagal syncope
Age Group: mean 32 years
Sex: M+F
Population Size: 7
Sources:
Paresthesia 1 patient
20 mg 1 times / day multiple, oral
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, mean 32 years
n = 7
Health Status: unhealthy
Condition: vasovagal syncope
Age Group: mean 32 years
Sex: M+F
Population Size: 7
Sources:
Dyspnea 1.4%
20 mg 1 times / day multiple, oral
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, mean 42.9 years
n = 146
Health Status: unhealthy
Condition: obesity
Age Group: mean 42.9 years
Sex: M+F
Population Size: 146
Sources:
Ecchymosis 1.4%
20 mg 1 times / day multiple, oral
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, mean 42.9 years
n = 146
Health Status: unhealthy
Condition: obesity
Age Group: mean 42.9 years
Sex: M+F
Population Size: 146
Sources:
Hypertension 1.4%
20 mg 1 times / day multiple, oral
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, mean 42.9 years
n = 146
Health Status: unhealthy
Condition: obesity
Age Group: mean 42.9 years
Sex: M+F
Population Size: 146
Sources:
Insomnia 10.3%
20 mg 1 times / day multiple, oral
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, mean 42.9 years
n = 146
Health Status: unhealthy
Condition: obesity
Age Group: mean 42.9 years
Sex: M+F
Population Size: 146
Sources:
Increased appetite 11.6%
20 mg 1 times / day multiple, oral
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, mean 42.9 years
n = 146
Health Status: unhealthy
Condition: obesity
Age Group: mean 42.9 years
Sex: M+F
Population Size: 146
Sources:
Constipation 12.3%
20 mg 1 times / day multiple, oral
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, mean 42.9 years
n = 146
Health Status: unhealthy
Condition: obesity
Age Group: mean 42.9 years
Sex: M+F
Population Size: 146
Sources:
Dizziness 12.3%
20 mg 1 times / day multiple, oral
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, mean 42.9 years
n = 146
Health Status: unhealthy
Condition: obesity
Age Group: mean 42.9 years
Sex: M+F
Population Size: 146
Sources:
Nervousness 12.3%
20 mg 1 times / day multiple, oral
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, mean 42.9 years
n = 146
Health Status: unhealthy
Condition: obesity
Age Group: mean 42.9 years
Sex: M+F
Population Size: 146
Sources:
Paresthesia 3.4%
20 mg 1 times / day multiple, oral
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, mean 42.9 years
n = 146
Health Status: unhealthy
Condition: obesity
Age Group: mean 42.9 years
Sex: M+F
Population Size: 146
Sources:
Anorexia 32.2%
20 mg 1 times / day multiple, oral
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, mean 42.9 years
n = 146
Health Status: unhealthy
Condition: obesity
Age Group: mean 42.9 years
Sex: M+F
Population Size: 146
Sources:
Dry mouth 32.2%
20 mg 1 times / day multiple, oral
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, mean 42.9 years
n = 146
Health Status: unhealthy
Condition: obesity
Age Group: mean 42.9 years
Sex: M+F
Population Size: 146
Sources:
Palpitation 4.1%
20 mg 1 times / day multiple, oral
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, mean 42.9 years
n = 146
Health Status: unhealthy
Condition: obesity
Age Group: mean 42.9 years
Sex: M+F
Population Size: 146
Sources:
Rash 4.1%
20 mg 1 times / day multiple, oral
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, mean 42.9 years
n = 146
Health Status: unhealthy
Condition: obesity
Age Group: mean 42.9 years
Sex: M+F
Population Size: 146
Sources:
Sweating 4.1%
20 mg 1 times / day multiple, oral
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, mean 42.9 years
n = 146
Health Status: unhealthy
Condition: obesity
Age Group: mean 42.9 years
Sex: M+F
Population Size: 146
Sources:
Taste perversion 4.1%
20 mg 1 times / day multiple, oral
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, mean 42.9 years
n = 146
Health Status: unhealthy
Condition: obesity
Age Group: mean 42.9 years
Sex: M+F
Population Size: 146
Sources:
Vasodilation 4.8%
20 mg 1 times / day multiple, oral
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, mean 42.9 years
n = 146
Health Status: unhealthy
Condition: obesity
Age Group: mean 42.9 years
Sex: M+F
Population Size: 146
Sources:
Dyspepsia 5.5%
20 mg 1 times / day multiple, oral
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, mean 42.9 years
n = 146
Health Status: unhealthy
Condition: obesity
Age Group: mean 42.9 years
Sex: M+F
Population Size: 146
Sources:
Tachycardia 6.8%
20 mg 1 times / day multiple, oral
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, mean 42.9 years
n = 146
Health Status: unhealthy
Condition: obesity
Age Group: mean 42.9 years
Sex: M+F
Population Size: 146
Sources:
Nausea 8.2%
20 mg 1 times / day multiple, oral
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, mean 42.9 years
n = 146
Health Status: unhealthy
Condition: obesity
Age Group: mean 42.9 years
Sex: M+F
Population Size: 146
Sources:
Asthenia 8.9%
20 mg 1 times / day multiple, oral
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, mean 42.9 years
n = 146
Health Status: unhealthy
Condition: obesity
Age Group: mean 42.9 years
Sex: M+F
Population Size: 146
Sources:
Hypertension <1.4%
Disc. AE
20 mg 1 times / day multiple, oral
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, mean 42.9 years
n = 146
Health Status: unhealthy
Condition: obesity
Age Group: mean 42.9 years
Sex: M+F
Population Size: 146
Sources:
Tachycardia <3%
Disc. AE
20 mg 1 times / day multiple, oral
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, mean 42.9 years
n = 146
Health Status: unhealthy
Condition: obesity
Age Group: mean 42.9 years
Sex: M+F
Population Size: 146
Sources:
Ecchymosis 0.5%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, mean 43.3 years
n = 203
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.3 years
Sex: M+F
Population Size: 203
Sources:
Sweating 1%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, mean 43.3 years
n = 203
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.3 years
Sex: M+F
Population Size: 203
Sources:
Dyspnea 1.5%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, mean 43.3 years
n = 203
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.3 years
Sex: M+F
Population Size: 203
Sources:
Constipation 10.8%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, mean 43.3 years
n = 203
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.3 years
Sex: M+F
Population Size: 203
Sources:
Dry mouth 16.7%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, mean 43.3 years
n = 203
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.3 years
Sex: M+F
Population Size: 203
Sources:
Increased appetite 16.7%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, mean 43.3 years
n = 203
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.3 years
Sex: M+F
Population Size: 203
Sources:
Anorexia 18.7%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, mean 43.3 years
n = 203
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.3 years
Sex: M+F
Population Size: 203
Sources:
Taste perversion 2%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, mean 43.3 years
n = 203
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.3 years
Sex: M+F
Population Size: 203
Sources:
Vasodilation 2%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, mean 43.3 years
n = 203
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.3 years
Sex: M+F
Population Size: 203
Sources:
Nausea 3.4%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, mean 43.3 years
n = 203
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.3 years
Sex: M+F
Population Size: 203
Sources:
Paresthesia 3.9%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, mean 43.3 years
n = 203
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.3 years
Sex: M+F
Population Size: 203
Sources:
Dyspepsia 4.4%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, mean 43.3 years
n = 203
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.3 years
Sex: M+F
Population Size: 203
Sources:
Tachycardia 4.4%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, mean 43.3 years
n = 203
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.3 years
Sex: M+F
Population Size: 203
Sources:
Hypertension 4.9%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, mean 43.3 years
n = 203
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.3 years
Sex: M+F
Population Size: 203
Sources:
Palpitation 4.9%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, mean 43.3 years
n = 203
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.3 years
Sex: M+F
Population Size: 203
Sources:
Rash 4.9%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, mean 43.3 years
n = 203
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.3 years
Sex: M+F
Population Size: 203
Sources:
Nervousness 6.4%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, mean 43.3 years
n = 203
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.3 years
Sex: M+F
Population Size: 203
Sources:
Asthenia 7.9%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, mean 43.3 years
n = 203
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.3 years
Sex: M+F
Population Size: 203
Sources:
Dizziness 7.9%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, mean 43.3 years
n = 203
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.3 years
Sex: M+F
Population Size: 203
Sources:
Insomnia 9.4%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, mean 43.3 years
n = 203
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.3 years
Sex: M+F
Population Size: 203
Sources:
Hypertension <2%
Disc. AE
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, mean 43.3 years
n = 203
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.3 years
Sex: M+F
Population Size: 203
Sources:
Tachycardia <3%
Disc. AE
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, mean 43.3 years
n = 203
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.3 years
Sex: M+F
Population Size: 203
Sources:
Paresthesia 1.3%
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 151
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 151
Sources:
Asthenia 10.6%
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 151
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 151
Sources:
Nervousness 11.3%
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 151
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 151
Sources:
Dyspepsia 12.6%
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 151
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 151
Sources:
Nausea 12.6%
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 151
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 151
Sources:
Ecchymosis 2%
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 151
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 151
Sources:
Hypertension 2%
Disc. AE
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 151
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 151
Sources:
Sweating 2.6%
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 151
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 151
Sources:
Tachycardia 2.6%
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 151
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 151
Sources:
Increased appetite 21.2%
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 151
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 151
Sources:
Insomnia 24.5%
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 151
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 151
Sources:
Tachycardia 3%
Disc. AE
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 151
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 151
Sources:
Hypertension 3.3%
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 151
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 151
Sources:
Anorexia 31.8%
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 151
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 151
Sources:
Dry mouth 31.8%
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 151
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 151
Sources:
Dyspnea 4.6%
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 151
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 151
Sources:
Taste perversion 4.6%
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 151
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 151
Sources:
Vasodilation 5.3%
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 151
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 151
Sources:
Palpitation 6%
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 151
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 151
Sources:
Rash 7.3%
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 151
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 151
Sources:
Constipation 7.9%
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 151
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 151
Sources:
Dizziness 7.9%
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 151
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 151
Sources:
Dyspnea 0.6%
5 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 169
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 169
Sources:
Ecchymosis 1.2%
5 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 169
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 169
Sources:
Hypertension 1.2%
5 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 169
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 169
Sources:
Sweating 1.2%
5 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 169
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 169
Sources:
Taste perversion 1.2%
5 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 169
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 169
Sources:
Tachycardia 1.8%
5 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 169
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 169
Sources:
Dry mouth 11.8%
5 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 169
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 169
Sources:
Constipation 13%
5 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 169
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 169
Sources:
Increased appetite 16.6%
5 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 169
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 169
Sources:
Anorexia 18.9%
5 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 169
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 169
Sources:
Paresthesia 2.4%
5 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 169
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 169
Sources:
Vasodilation 2.4%
5 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 169
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 169
Sources:
Dyspepsia 4.1%
5 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 169
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 169
Sources:
Nausea 4.1%
5 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 169
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 169
Sources:
Rash 4.1%
5 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 169
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 169
Sources:
Nervousness 5.3%
5 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 169
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 169
Sources:
Asthenia 7.1%
5 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 169
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 169
Sources:
Insomnia 8.3%
5 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 169
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 169
Sources:
Dizziness 8.9%
5 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 169
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 169
Sources:
Hypertension <1.2%
Disc. AE
5 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 169
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 169
Sources:
Tachycardia <1.8%
Disc. AE
5 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, mean 43.4 years
n = 169
Health Status: unhealthy
Condition: obesity
Age Group: mean 43.4 years
Sex: M+F
Population Size: 169
Sources:
Dyspnea 1%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
unhealthy, mean 44.2 years
n = 196
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.2 years
Sex: M+F
Population Size: 196
Sources:
Insomnia 10.2%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
unhealthy, mean 44.2 years
n = 196
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.2 years
Sex: M+F
Population Size: 196
Sources:
Constipation 11.7%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
unhealthy, mean 44.2 years
n = 196
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.2 years
Sex: M+F
Population Size: 196
Sources:
Increased appetite 14.3%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
unhealthy, mean 44.2 years
n = 196
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.2 years
Sex: M+F
Population Size: 196
Sources:
Paresthesia 2%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
unhealthy, mean 44.2 years
n = 196
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.2 years
Sex: M+F
Population Size: 196
Sources:
Vasodilation 2%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
unhealthy, mean 44.2 years
n = 196
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.2 years
Sex: M+F
Population Size: 196
Sources:
Palpitation 2.6%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
unhealthy, mean 44.2 years
n = 196
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.2 years
Sex: M+F
Population Size: 196
Sources:
Sweating 2.6%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
unhealthy, mean 44.2 years
n = 196
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.2 years
Sex: M+F
Population Size: 196
Sources:
Taste perversion 2.6%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
unhealthy, mean 44.2 years
n = 196
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.2 years
Sex: M+F
Population Size: 196
Sources:
Anorexia 21.4%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
unhealthy, mean 44.2 years
n = 196
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.2 years
Sex: M+F
Population Size: 196
Sources:
Dry mouth 25.5%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
unhealthy, mean 44.2 years
n = 196
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.2 years
Sex: M+F
Population Size: 196
Sources:
Ecchymosis 3.1%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
unhealthy, mean 44.2 years
n = 196
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.2 years
Sex: M+F
Population Size: 196
Sources:
Hypertension 5.1%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
unhealthy, mean 44.2 years
n = 196
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.2 years
Sex: M+F
Population Size: 196
Sources:
Nausea 5.1%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
unhealthy, mean 44.2 years
n = 196
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.2 years
Sex: M+F
Population Size: 196
Sources:
Asthenia 6.1%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
unhealthy, mean 44.2 years
n = 196
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.2 years
Sex: M+F
Population Size: 196
Sources:
Rash 7.1%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
unhealthy, mean 44.2 years
n = 196
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.2 years
Sex: M+F
Population Size: 196
Sources:
Nervousness 7.7%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
unhealthy, mean 44.2 years
n = 196
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.2 years
Sex: M+F
Population Size: 196
Sources:
Tachycardia 7.7%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
unhealthy, mean 44.2 years
n = 196
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.2 years
Sex: M+F
Population Size: 196
Sources:
Dizziness 8.2%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
unhealthy, mean 44.2 years
n = 196
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.2 years
Sex: M+F
Population Size: 196
Sources:
Dyspepsia 8.2%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
unhealthy, mean 44.2 years
n = 196
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.2 years
Sex: M+F
Population Size: 196
Sources:
Hypertension <2%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
unhealthy, mean 44.2 years
n = 196
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.2 years
Sex: M+F
Population Size: 196
Sources:
Tachycardia <3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
unhealthy, mean 44.2 years
n = 196
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.2 years
Sex: M+F
Population Size: 196
Sources:
Tachycardia 0.7%
1 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy, mean 44.5 years
n = 149
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.5 years
Sex: M+F
Population Size: 149
Sources:
Taste perversion 0.7%
1 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy, mean 44.5 years
n = 149
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.5 years
Sex: M+F
Population Size: 149
Sources:
Dyspnea 1.3%
1 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy, mean 44.5 years
n = 149
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.5 years
Sex: M+F
Population Size: 149
Sources:
Vasodilation 1.3%
1 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy, mean 44.5 years
n = 149
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.5 years
Sex: M+F
Population Size: 149
Sources:
Increased appetite 11.4%
1 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy, mean 44.5 years
n = 149
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.5 years
Sex: M+F
Population Size: 149
Sources:
Insomnia 12.1%
1 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy, mean 44.5 years
n = 149
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.5 years
Sex: M+F
Population Size: 149
Sources:
Hypertension 2%
1 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy, mean 44.5 years
n = 149
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.5 years
Sex: M+F
Population Size: 149
Sources:
Palpitations 2%
1 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy, mean 44.5 years
n = 149
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.5 years
Sex: M+F
Population Size: 149
Sources:
Paresthesia 2%
1 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy, mean 44.5 years
n = 149
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.5 years
Sex: M+F
Population Size: 149
Sources:
Asthenia 2.7%
1 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy, mean 44.5 years
n = 149
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.5 years
Sex: M+F
Population Size: 149
Sources:
Anorexia 20.1%
1 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy, mean 44.5 years
n = 149
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.5 years
Sex: M+F
Population Size: 149
Sources:
Nausea 3.4%
1 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy, mean 44.5 years
n = 149
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.5 years
Sex: M+F
Population Size: 149
Sources:
Dyspepsia 4%
1 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy, mean 44.5 years
n = 149
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.5 years
Sex: M+F
Population Size: 149
Sources:
Dizziness 4.7%
1 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy, mean 44.5 years
n = 149
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.5 years
Sex: M+F
Population Size: 149
Sources:
Nervousness 4.7%
1 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy, mean 44.5 years
n = 149
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.5 years
Sex: M+F
Population Size: 149
Sources:
Rash 5.4%
1 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy, mean 44.5 years
n = 149
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.5 years
Sex: M+F
Population Size: 149
Sources:
Dry mouth 6%
1 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy, mean 44.5 years
n = 149
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.5 years
Sex: M+F
Population Size: 149
Sources:
Constipation 6.7%
1 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy, mean 44.5 years
n = 149
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.5 years
Sex: M+F
Population Size: 149
Sources:
Tachycardia <0.7%
Disc. AE
1 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy, mean 44.5 years
n = 149
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.5 years
Sex: M+F
Population Size: 149
Sources:
Hypertension <2%
Disc. AE
1 mg 1 times / day multiple, oral
Minumum effective dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy, mean 44.5 years
n = 149
Health Status: unhealthy
Condition: obesity
Age Group: mean 44.5 years
Sex: M+F
Population Size: 149
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [IC50 0.829 uM]
yes [IC50 15.6 uM]
yes [IC50 29 uM]
yes [IC50 >50 uM]
yes [IC50 >50 uM]
yes [IC50 >50 uM]
yes [IC50 >50 uM]
yes [IC50 >50 uM]
yes [IC50 >50 uM]
yes [IC50 >50 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
yes
yes
yes
yes
yes (co-administration study)
Comment: Ketoconazole: resulted in moderate increases in AUC and Cmax of 58% and 36% for M1 and of 20% and 19% for M2, respectively; Erythromycin: resulted in small increases in the AUC (less than 14%) for M1 and M2. A small reduction in Cmax for M1 (11%) and a slight increase in Cmax for M2 (10%) were observed. Other tested drugs that are substrates and/or inhibitors of CYP 450 isozymes were tested. Cimetidine: resulted insmall increases in combined (M1 and M2) plasma Cmax (3.4%) and AUC (7.3%); Simvastatin: no significant effect on plasma Cmax and AUC of M2 or M1 and M2 combined. The Cmax (16%) and AUC (12%) of M1 were slightly decreased. Simvastatin slightly decreased sibutramine Cmax (14%) and AUC (21%); Omeprazole: slightly increased plasma Cmax and AUC of M1 and M2 combined (approximately 15%). M2 Cmax and AUC were not significantly affected whereas M1 Cmax (30%) and AUC (40%) were modestly increased. Plasma Cmax (57%) and AUC (67%) of unchanged sibutramine were moderately increased; Olanzapine: Olanzapine had no significant effect on plasma Cmax and AUC of M2 and M1 and M2 combined, or the AUC of M1; Lorazepam: Lorazepam had no significant effect on the pharmacokinetics of sibutramine metabolites M1 and M2.
Page: 3.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Dexfenfluramine. An updated review of its therapeutic use in the management of obesity.
1996 Nov
Sibutramine: a review of the pharmacology of a novel anti-obesity agent.
1997 Mar
Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine.
1998 Aug
Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity.
1999 Sep
[Obesity: principles of drug therapy].
2000 Aug
An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action.
2000 Oct
Sibutramine in overweight/obese hypertensive patients.
2001 Dec
Organic hypomania secondary to sibutramine-citalopram interaction.
2002 Feb
Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
2002 Jan
Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction.
2002 Sep
Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials.
2003 Dec
The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis.
2003 Sep
[Pharmacotherapy of obesity].
2004 Oct 7
Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
2006 May
Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study.
2007 Apr 17
Open channel block of A-type, kv4.3, and delayed rectifier K+ channels, Kv1.3 and Kv3.1, by sibutramine.
2007 May
Myocardial infarction induced by appetite suppressants in Malaysia.
2007 Nov 1
The endocannabinoid system as a target for obesity treatment.
2008
[Pharmacological therapy of obesity].
2008 Apr
Sibutramine: current status as an anti-obesity drug and its future perspectives.
2008 Aug
Sibutramine-induced acute myocardial infarction in a young lady.
2008 Nov
The use of sibutramine in the management of obesity and related disorders: an update.
2009
Pharmacotherapy for obesity.
2009 Dec
Long-term effects of weight-reducing drugs in hypertensive patients.
2009 Jul 8
Sibutramine versus continuous positive airway pressure in obese obstructive sleep apnoea patients.
2009 Sep
Multiple effects of sibutramine on ejaculation and on vas deferens and seminal vesicle contractility.
2009 Sep 15
Oleanolic acid, a natural triterpenoid improves blood glucose tolerance in normal mice and ameliorates visceral obesity in mice fed a high-fat diet.
2010 Apr 15
Diabesity: therapeutic options.
2010 Jun
[32-year-old patient with acute myocardial infarction possibly induced by the appetite suppressant sibutramine].
2010 May
The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease.
2010 May
Elevation of QT dispersion after obesity drug sibutramine.
2010 Nov
[Long-term effects of weight-reducing drugs in hypertensive patients--a survey of a Cochrane review].
2011 Feb 21
Effects of oral anorexiant sibutramine on the expression of cytochromes P450s in human hepatocytes and cancer cell lines.
2013 Dec
Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes.
2013 Sep 5
Bridging Functional and Structural Cardiotoxicity Assays Using Human Embryonic Stem Cell-Derived Cardiomyocytes for a More Comprehensive Risk Assessment.
2015 Nov
Patents

Sample Use Guides

The recommended starting dose is 10 mg administered once daily with or without food.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Jun 26 02:20:24 UTC 2021
Edited
by admin
on Sat Jun 26 02:20:24 UTC 2021
Record UNII
WV5EC51866
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SIBUTRAMINE
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
SIBUTRAMINE [MI]
Common Name English
(+/-)-SIBUTRAMINE
Common Name English
(+/-)-1-(P-CHLOROPHENYL)-.ALPHA.-ISOBUTYL-N,N-DIMETHYLCYCLOBUTANEMETHYLAMINE
Common Name English
SIBUTRAMINE [WHO-DD]
Common Name English
RACEMIC SIBUTRAMINE
Common Name English
SIBUTRAMINE [INN]
Common Name English
BUTRAMIN
Brand Name English
CYCLOBUTANEMETHANAMINE, 1-(4-CHLOROPHENYL)-N,N-DIMETHYL-.ALPHA.-(2-METHYLPROPYL)-
Systematic Name English
1-(4-CHLOROPHENYL)-N,N-DIMETHYL-.ALPHA.-(2-METHYLPROPYL)CYCLOBUTANEMETHANAMINE
Systematic Name English
MEDARIA
Brand Name English
CF-ALLI
Brand Name English
SIBUTRAMINE [VANDF]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175372
Created by admin on Sat Jun 26 02:20:25 UTC 2021 , Edited by admin on Sat Jun 26 02:20:25 UTC 2021
NDF-RT N0000175372
Created by admin on Sat Jun 26 02:20:25 UTC 2021 , Edited by admin on Sat Jun 26 02:20:25 UTC 2021
WHO-ATC A08AA10
Created by admin on Sat Jun 26 02:20:25 UTC 2021 , Edited by admin on Sat Jun 26 02:20:25 UTC 2021
NDF-RT N0000175424
Created by admin on Sat Jun 26 02:20:25 UTC 2021 , Edited by admin on Sat Jun 26 02:20:25 UTC 2021
DEA NO. 1675
Created by admin on Sat Jun 26 02:20:25 UTC 2021 , Edited by admin on Sat Jun 26 02:20:25 UTC 2021
WHO-VATC QA08AA10
Created by admin on Sat Jun 26 02:20:25 UTC 2021 , Edited by admin on Sat Jun 26 02:20:25 UTC 2021
NDF-RT N0000000102
Created by admin on Sat Jun 26 02:20:25 UTC 2021 , Edited by admin on Sat Jun 26 02:20:25 UTC 2021
NDF-RT N0000000114
Created by admin on Sat Jun 26 02:20:25 UTC 2021 , Edited by admin on Sat Jun 26 02:20:25 UTC 2021
NDF-RT N0000000109
Created by admin on Sat Jun 26 02:20:25 UTC 2021 , Edited by admin on Sat Jun 26 02:20:25 UTC 2021
NCI_THESAURUS C29728
Created by admin on Sat Jun 26 02:20:25 UTC 2021 , Edited by admin on Sat Jun 26 02:20:25 UTC 2021
LIVERTOX 884
Created by admin on Sat Jun 26 02:20:25 UTC 2021 , Edited by admin on Sat Jun 26 02:20:25 UTC 2021
Code System Code Type Description
RXCUI
36514
Created by admin on Sat Jun 26 02:20:25 UTC 2021 , Edited by admin on Sat Jun 26 02:20:25 UTC 2021
PRIMARY RxNorm
ChEMBL
CHEMBL1419
Created by admin on Sat Jun 26 02:20:25 UTC 2021 , Edited by admin on Sat Jun 26 02:20:25 UTC 2021
PRIMARY
WIKIPEDIA
SIBUTRAMINE
Created by admin on Sat Jun 26 02:20:25 UTC 2021 , Edited by admin on Sat Jun 26 02:20:25 UTC 2021
PRIMARY
IUPHAR
2586
Created by admin on Sat Jun 26 02:20:25 UTC 2021 , Edited by admin on Sat Jun 26 02:20:25 UTC 2021
PRIMARY
FDA UNII
WV5EC51866
Created by admin on Sat Jun 26 02:20:25 UTC 2021 , Edited by admin on Sat Jun 26 02:20:25 UTC 2021
PRIMARY
PUBCHEM
5210
Created by admin on Sat Jun 26 02:20:25 UTC 2021 , Edited by admin on Sat Jun 26 02:20:25 UTC 2021
PRIMARY
EVMPD
SUB10512MIG
Created by admin on Sat Jun 26 02:20:25 UTC 2021 , Edited by admin on Sat Jun 26 02:20:25 UTC 2021
PRIMARY
DRUG BANK
DB01105
Created by admin on Sat Jun 26 02:20:25 UTC 2021 , Edited by admin on Sat Jun 26 02:20:25 UTC 2021
PRIMARY
INN
6124
Created by admin on Sat Jun 26 02:20:25 UTC 2021 , Edited by admin on Sat Jun 26 02:20:25 UTC 2021
PRIMARY
NCI_THESAURUS
C75965
Created by admin on Sat Jun 26 02:20:25 UTC 2021 , Edited by admin on Sat Jun 26 02:20:25 UTC 2021
PRIMARY
MESH
C058254
Created by admin on Sat Jun 26 02:20:25 UTC 2021 , Edited by admin on Sat Jun 26 02:20:25 UTC 2021
PRIMARY
DRUG CENTRAL
2440
Created by admin on Sat Jun 26 02:20:25 UTC 2021 , Edited by admin on Sat Jun 26 02:20:25 UTC 2021
PRIMARY
CAS
106650-56-0
Created by admin on Sat Jun 26 02:20:25 UTC 2021 , Edited by admin on Sat Jun 26 02:20:25 UTC 2021
PRIMARY
LACTMED
Sibutramine
Created by admin on Sat Jun 26 02:20:25 UTC 2021 , Edited by admin on Sat Jun 26 02:20:25 UTC 2021
PRIMARY
EPA CompTox
106650-56-0
Created by admin on Sat Jun 26 02:20:25 UTC 2021 , Edited by admin on Sat Jun 26 02:20:25 UTC 2021
PRIMARY
HSDB
7209
Created by admin on Sat Jun 26 02:20:25 UTC 2021 , Edited by admin on Sat Jun 26 02:20:25 UTC 2021
PRIMARY
MERCK INDEX
M9894
Created by admin on Sat Jun 26 02:20:25 UTC 2021 , Edited by admin on Sat Jun 26 02:20:25 UTC 2021
PRIMARY Merck Index
Related Record Type Details
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
ENANTIOMER -> RACEMATE
SALT/SOLVATE -> PARENT
ENANTIOMER -> RACEMATE
BINDER->LIGAND
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE ACTIVE -> PARENT
METABOLITE -> PARENT
Related Record Type Details
ACTIVE MOIETY